𝔖 Bobbio Scriptorium
✦   LIBER   ✦

257 EFFICACY AND SAFETY OF TEVERELIX LA, A NEW GNRH ANTAGONIST IN PATIENTS WITH ADVANCED PROSTATE CANCER. RESULTS FROM A PHASE II MULTI-CENTRE, OPEN-LABEL, PILOT STUDY INVESTIGATING AN INITIAL

✍ Scribed by C. Maclean; F. Larsen; J. Drewe; A. Ulys; D. Kaniušas

Book ID
119617589
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
328 KB
Volume
6
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

346 EFFICACY AND SAFETY OF TEVERELIX LA,
346 EFFICACY AND SAFETY OF TEVERELIX LA, A NEW GNRH ANTAGONIST IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH). RESULTS FROM A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, MULTINATIONAL STUDY INVESTIGATING TWO SINGLE INJECTIONS OF 60 MG AT 48 HOURS INTERVAL ADMINISTERED S.C. TO TREATMENT NAÏVE PATIENTS SUFFERING FROM BPH
✍ C. Maclean; F. Larsen; J. Drewe; A.V. Dzmitryieu; A. Gres; A. Strockyi; V. Dovge 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 332 KB
EFFICACY AND SAFETY OF TEVERELIX LA, A N
EFFICACY AND SAFETY OF TEVERELIX LA, A NEW GNRH ANTAGONIST IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH). RESULTS FROM A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, MULTINATIONAL STUDY INVESTIGATING TWO SINGLE INJECTIONS OF 30 MG OR 60 MG (SEPARATED BY AT LEAST 12 WEEKS) ADMINISTERED SC TO TREATMENT NAIVE PATIENTS SUFFERING FROM BPH
✍ C.M. Maclean; L. Skillern; F. Larsen; A. Gres; A. Strotski; A.V. Dmitrijev; V.K. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 71 KB